Inogen Inc (NASDAQ:INGN) insider Scott Wilkinson sold 30,651 shares of the company’s stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $115.75, for a total transaction of $3,547,853.25. Following the completion of the sale, the insider now directly owns 38,107 shares in the company, valued at approximately $4,410,885.25. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Shares of Inogen Inc (INGN) traded down $0.96 during midday trading on Friday, reaching $114.99. 99,500 shares of the company traded hands, compared to its average volume of 174,217. The firm has a market cap of $2,380.00, a P/E ratio of 80.41, a price-to-earnings-growth ratio of 3.93 and a beta of 1.13. Inogen Inc has a 1-year low of $62.69 and a 1-year high of $130.05.

Inogen (NASDAQ:INGN) last issued its quarterly earnings results on Tuesday, November 7th. The medical technology company reported $0.33 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.29 by $0.04. The business had revenue of $69.00 million for the quarter, compared to the consensus estimate of $63.55 million. Inogen had a net margin of 11.36% and a return on equity of 13.37%. The firm’s quarterly revenue was up 26.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.25 EPS. analysts predict that Inogen Inc will post 1.19 EPS for the current year.

INGN has been the topic of several analyst reports. Zacks Investment Research raised shares of Inogen from a “hold” rating to a “buy” rating and set a $128.00 target price on the stock in a report on Tuesday, January 9th. BidaskClub lowered shares of Inogen from a “buy” rating to a “hold” rating in a report on Tuesday, December 5th. Leerink Swann reaffirmed an “outperform” rating and issued a $120.00 target price (up previously from $115.00) on shares of Inogen in a report on Wednesday, November 8th. Finally, Needham & Company LLC upped their target price on shares of Inogen from $108.00 to $125.00 and gave the stock a “strong-buy” rating in a report on Wednesday, November 8th. One analyst has rated the stock with a sell rating, four have assigned a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $102.71.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Piedmont Investment Advisors LLC acquired a new position in Inogen during the 2nd quarter worth about $336,000. Parametric Portfolio Associates LLC lifted its position in Inogen by 63.6% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 45,969 shares of the medical technology company’s stock worth $4,386,000 after buying an additional 17,867 shares in the last quarter. Vanguard Group Inc. lifted its position in Inogen by 24.9% during the 2nd quarter. Vanguard Group Inc. now owns 1,515,342 shares of the medical technology company’s stock worth $144,594,000 after buying an additional 301,737 shares in the last quarter. Koch Industries Inc. lifted its position in Inogen by 19,485.8% during the 2nd quarter. Koch Industries Inc. now owns 657,102 shares of the medical technology company’s stock worth $650,000 after buying an additional 653,747 shares in the last quarter. Finally, BlackRock Inc. lifted its position in Inogen by 1.9% during the 2nd quarter. BlackRock Inc. now owns 2,150,552 shares of the medical technology company’s stock worth $205,207,000 after buying an additional 39,752 shares in the last quarter.

ILLEGAL ACTIVITY NOTICE: This report was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another website, it was illegally copied and reposted in violation of international trademark & copyright legislation. The original version of this report can be read at https://www.thecerbatgem.com/2018/01/19/scott-wilkinson-sells-30651-shares-of-inogen-inc-ingn-stock.html.

Inogen Company Profile

Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.

Insider Buying and Selling by Quarter for Inogen (NASDAQ:INGN)

Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.